Ginkgo Bioworks 10-K Waiting for Royalties. $314 million of Total revenue in 2021, representing an increase of 309% over 2020 31 new Cell Programs added in 2021, representing 72% growth over 2020 Over. Ginkgo Bioworks reported its 2021 financials Thursday, and the $1.7 billion of stock-based compensation caught everyone's attention. Ginkgo brought in $88 million in revenue in the first half of 2021, nearly triple the $31 million from the same period in 2020. Ginkgo helps drugmakers, consumer brands, and agricultural companies develop specialized microbes. Over $1.5 billion cash balance, providing meaningful multi-year runway as we drive towards profitability. Ginkgo reported $59 million in foundry revenue for 2020, and . Peak Revenue. View the FULL LIST: 2020 DISRUPTOR 50. . August 6, 2020 1347 9. Revenues from the foundry business rose to $44 million from $31 million in H1 2020. new revenue-paying customer. Stmt Update Type--Currency Code. Some biotech investors believe this valuation is excessive for a company with little revenue; in 2020 Ginkgo brought in $77 million providing research services and covid-19 tests but lost plenty . Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial . The . The honeymoon for newly minted Ginkgo Bioworks . Do NOT follow this link! Total Revenue. Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), the leading horizontal platform for cell programming, today announced its results for the fourth quarter and year ended December 31, 2021. Jason Kelly, co-founder and CEO of Ginkgo Bioworks, joins "Squawk Box" to discuss the type of work the company is doing to . Period End Date. Ginkgo Bioworks has made 5 investments. Similar to our recent articles on AbCellera and Recursion Pharmaceuticals, . Unsafe for Black People. The company specializes in using genetic engineering to produce . Foundry revenue $ 34,156 . Income (Quarterly) Future Periods. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial . March 28, 2022 - 4:01 pm. Corporate Profile. The. 2021 2020 2021 2020 Foundry revenue (related party revenue of $ 13,124 and $ 7,270 for the three months ended September 30, 2021 and 2020, respectively, and . Our cell programming platform enables the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals. The company also reported revenues of $44 million from its biosecurity business for the first half of the year, relative to its original projection for full-year revenues of $50 million. Net revenue was $2.2 million in Q1 2020, of which the primary contributors to revenue in the quarter were the continued distribution of products in both e-commerce and physical retail channels and the introduction of Lord Jones™ Acid Mantle Repair CBD Moisturizer. Ginkgo Bioworks Holdings Income Statement. - Life Sciences Reporter, Boston Business Journal. Biosecurity Revenue: Includes revenue generated from offering COVID-19 testing products and services for businesses, academic institutions, and other organizations. Foundry revenue of $34.7 million in Q3 and $78.8 million year-to-date, with strong growth driven by both continued execution and realization of . If the company was able to generate a gross profit, though, it didn't bother . Revenue Recognition . 2021-09 . 2020. See insights on Ginkgo Bioworks including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. 2020. Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results. MarketWatch. company was founded in 2009 and is headquartered in Boston, Massachusetts. Net Income Growth-Sales or Revenue: 148.49 M: Sales or Revenue Growth-EBITDA-1.68 B: 2021 5-year . Corporate Profile. ; Gross profit was $1.1 million in Q1 2020, representing a gross margin of 50%. Many were now millionaires, while Ginkgo's five founders' stakes approached $1 . $314 million of Total revenue in 2021, representing an increase of 309% over 2020. Ginkgo Bioworks Lab/Courtesy Ginkgo Bioworks. Ginkgo Bioworks 10-K Waiting for Royalties. Ginkgo Bioworks has 599 employees at their 1 location. It's expected to raise about $1.6 billion for the company. Ginkgo Bioworks's annual revenues are $100-$500 million (see exact revenue data) and has 100-500 employees. Ginkgo has also actively supported a number of COVID . Ginkgo Bioworks reportedly explores $20B SPAC deal. 2 min read. Notes to Condensed Consolidated Financial Statements (unaudited) 1. Our cell programming platform enables the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals. Ginkgo Bioworks Holdings, Inc. is a biotech company. Organization . Ginkgo Bioworks Holdings (22%) Founded in 2008, it is a biotech company. Their most recent investment was on Oct 22, 2020, when Allonnia raised $40M. Over $1.5 billion cash balance, providing meaningful multi-year runway as we drive towards profitability. Our revenue is concentrated in . As Putin eyes a date to declare victory, here's a Ukraine . Concentric; June 18, 2020. Stmt Source Date. . MarketWatch. Ginkgo Bioworks Holdings, Inc. and Subsidiaries . FinSMEs. Ginkgo has over 70 customer partners . First Quarter 2020. As a black woman, my experience at Ginkgo Bioworks was the worst. It is headquartered in Calgary, Canada. Ginkgo Bioworks Holdings annual revenue for was $0B, a NAN% decline from . $314 million of Total revenue in 2021, representing an increase of 309% over 2020. Ginkgo Bioworks, Inc. and Subsidiaries . Ginkgo Bioworks Holdings revenue for the twelve months ending September 30, 2021 was $0.078B, a 483.45% increase year-over-year. GINKGO BIOWORKS MEDIA CONTACT: . Ginkgo Bioworks. Ginkgo Bioworks Contacts: INVESTOR CONTACT: . . Ginkgo expects Total revenue of $325 to $340 million in 2022. . The company projects growing revenue and adjusted EBITDA from $77 million and negative $121 million, respectively, in 2020 to $1.1 billion and $166 . Ginkgo Bioworks Holdings Inc has been hit with a shareholder suit claiming it mispresented its revenue sources in statements about its $15 billion merger with a blank check company. $314 million of Total revenue in 2021, representing an increase of 309% over 2020. Ginkgo Bioworks is a biotechnology company developing horizontal platform for cell programming that is used to program cells on behalf of their customers. Synthetic biology pioneer Ginkgo Bioworks said today it will become a public company through a $17.5 billion merger with a special purpose acquisition company (SPAC) that is expected to provide up to $2.5 billion of gross cash proceeds. Q4 wasn't just a fluke, either. Ginkgo Bioworks Gets Stung. Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 . 2020. The management is biased and rewards a specific group more than others. Ginkgo Bioworks — The Next AWS . Ginkgo's cell programming platform generated about $34.7 million in revenue, up from $11.5 million during the same quarter in 2020. Next Period. TABLE OF CONTENTS : Page : . Ginkgo Bioworks Holdings, Inc. and Subsidiaries . For the years ended December 31, 2021 and 2020, royalties did not comprise a material amount of our revenue. Over $1.5 billion cash balance, providing meaningful multi-year runway as we drive towards profitability. 2021. It is classified as operating in the Scientific Research & Development Services industry. We've been huge fans of the work Ginkgo is doing, but this report raised some concerns. Revenue of $5.96 billion was more than the $5.91 billion analysts had expected. September 2021 - September 2020 Last Period Last. The company expects to generate $150 million of revenue in 2021, representing approximately 96% growth from 2020. For Fiscal 2021, Ginkgo Bioworks pulled in total revenue of $314 million, marking a year-over-year increase of 309%. Menu icon A vertical stack of three evenly spaced horizontal lines. Ginkgo Bioworks H1 2021 Revenues Nearly Triple Aug 18, 2021 . The report alleges that "[t]he majority of [Ginkgo Bioworks'] foundry revenue, an absurd 72% in 2020, and essentially 100% of its deferred revenue are derived from related-party 'customers . 31 new Cell Programs added in 2021, representing 72% growth over 2020. , together with a notice to the Internal Revenue Service prepared in accordance with the provisions of Treasury Regulations Section 1.897-2(h)(2) . BOSTON, Nov. 15, 2021 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), the leading horizontal platform for cell programming, . 2021. FISCAL 2020 FINANCIAL RESULTS. Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results. Bloomberg; June 18, 2020. $314 million of Total revenue in 2021, representing an increase of 309% over 2020. . Third quarter 2021 Foundry revenue of $34.7 million, up from $11.5 million in the comparable prior-year period, an increase of 202%. Read More. It works with companies to make engineered molecules for plant . 12/31/2020. First Period First. 2021. Ginkgo Bioworks, a synthetic biology company now valued at around $15 billion, begins trading on the New York Stock Exchange today. . $314 million of Total revenue in 2021, representing an increase of 309% over 2020. After extensive research and analysis, Zippia's data science team found the following key financial metrics. 2020: 2021: 2020: Foundry revenue (related party revenue of $13,124 and $7,270 for the three months ended September 30, 2021 and 2020, respectively, and $36,746 and . Ginkgo Bioworks Holdings annual revenue for 2020 was $0B, a NAN% decline from . Headquartered in Boston, Ginkgo Bioworks is building a platform to enable customers to program cells as easily as we can program computers. GINKGO BIOWORKS, INC. dated as of May 11, 2021 . 12/31/2020. Ginkgo BioWorks CEO on New Covid-19 Testing Initiative. Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results. GINKGO BIOWORKS MEDIA CONTACT: . 0.0 . Clearly, cell-programming science can be a remarkably lucrative field of business. GINKGO BIOWORKS HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) . The recent $17.5 billion valuation is due to a SPAC merger with Soaring Eagle to make Ginkgo Bioworks a publicly traded company under the ticker symbol "DNA". Over $1.5 billion cash balance, providing meaningful multi-year runway as we drive towards profitability. 12/31/2021 . It's easy enough to dismiss all the interviews conducted by Scorpion. Ten years of annual and quarterly financial statements and annual report data for Ginkgo Bioworks Holdings (DNA). 31 new Cell Programs added in 2021 . Ginkgo Bioworks has invested in Synlogic on Oct 22, 2020. 2020 and 2019, respectively, and as of December 31, 2021, Ginkgo had an accumulated deficit of approximately $2,297.9 million. In that time frame, the company managed to increase its revenue year-over-year by a whopping 363%, to $148 million. 2020. Shares of synthetic biology company Ginkgo Bioworks Holdings Inc (NYSE: DNA) traded lower by more than 20% on Wednesday. Ginkgo Bioworks revenue is $5.3M annually. GINKGO BIOWORKS HOLDINGS, INC. . 2021. Ginkgo Bioworks this morning announced that it will be going public via the SPAC route with that of Soaring Eagle Acquisition Corp (NASDAQ: SRNG). Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders Ginkgo Bioworks is a biotech company from the United States founded in 2009 by scientists from MIT and headed by Jason Kelly. | April 12, 2022 . Cash flow from operating activities: Net loss $ (231,647) $ (80,324) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization . Ginkgo Bioworks Reports Third Quarter 2021 Results Foundry revenue of $34.7 million in Q3 and $78.8 million year-to-date, with strong growth driven by both. Ginkgo expects Total revenue . Ginkgo Bioworks is a racist place with terrible work culture. 31 new Cell Programs added in 2021, representing 72% growth over 2020. In the last twelve months ended June 30, 2021, Ginkgo Bioworks reported revenue of US$ 133.1 million and a net loss of US$ 200.5 million. The company reported a net loss from operations of $1.7 billion. Ginkgo added 10 new programs in the fourth quarter alone. Income statements, balance sheets, cash flow statements and key ratios. This fund was announced on Oct 9, 2019 and raised a total of $350M. Revenue 77.61M 13.30M . Long story short, short-seller Scorpion Capital published a 175-page report on Ginkgo Bioworks which accused them of fraud. Ginkgo Bioworks Launches Concentric by Ginkgo to Help Enable Large-Scale COVID-19 Testing. Ginkgo Bioworks was started in 2009 by a team of MIT scientists intent on building made-to-order microbes that enable customers to grow rather than . 31 new Cell Programs added in 2021, representing 72% growth over 2020. 2020. Scorpion Capital found that related-party revenue for Ginkgo Bioworks was 65% of foundry revenue in 2019 and 72% of foundry revenue in 2020. For the rest of this year, the company sees multiple potential . When you look at Ginkgo Bioworks revenue and its valuation, you think it would be a great . Please visit investors.ginkgobioworks.com to view the update including a slide presentation with additional details on the third quarter and supplemental financial information, which will be posted following the call. Ginkgo Bioworks, a synthetic biology company now valued at around $15 billion, begins trading on the New York Stock Exchange today. Ginkgo Bioworks CEO on $1.1 billion loan for coronavirus efforts. The contributions from each of Ginkgo's revenue segments for the Six Months Ended June 30, 2021 in their 2021 S-1 filing were as follows: As Putin eyes a date to declare victory, here's a Ukraine . Format Export. 1h ago. Ginkgo Bioworks, a synthetic-biology company, is going public Friday via a $15 billion SPAC deal. Ginkgo Bioworks expects full-year 2022 revenue to be between $325 . Raymond James analyst Rahul Sarugaser continues to have great expectations for Ginkgo Bioworks Holdings, maintaining his "Outperform 2" rating and target price of $14.50/share in an update to . Premarket. Synbio revenue excluding Ginkgo Bioworks is expected to be in the range of $41 to $44 million NGS revenue is estimated to be in the range of $54 to $58 million Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), the leading horizontal platform for cell programming, today announced its results for the third quarter ended September 30, 2021. Foundry revenue (related party revenue . In terms of full-year financials, Ginkgo Bioworks reported $314 million in total revenue for the year, an increase of 309% over 2020. Ginkgo Bioworks Provides Preliminary Unaudited 2021 Revenue Highlights and Business Review & J.P. Morgan Healthcare Conference News Ginkgo released a press release today stating they anticipate to meet or exceed their 2021 projections that were revised upwards as part of their Q3 reporting. Ginkgo Bioworks reported adjusted EBITDA of $1 million, which was up from a loss of $51 million in the fourth quarter of 2020. Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results. Cenovus Energy Inc (NYSE:CVE) reported revenue of over $13.2 billion in 2020, down from over $20.1 billion in 2019. ET . "2020 Audited Financial Statements" has the meaning specified in Section 7.3. . Ginkgo Bioworks has 200 employees, and the revenue per employee ratio is $26,250. Condensed Consolidated Statements of Cash Flows (unaudited) (in thousands) Nine Months Ended September 30, 2021. Ginkgo Bioworks CEO on scaling up Covid-19 testing: 'If we try, we can win' CNBC; May 28, 2020 Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results Published: March 28, 2022 at 4:01 p.m. Biosecurity Revenue In 2020, the Company launched its commercial offering of COVID-19 testing products and services for businesses, academic institutions, . For the years ended December 31, 2021 and 2020, royalties did not comprise a material amount of our revenue. 12/31/2021. Top-line revenue in the first half of 2020 rose 180% to $88 million. 2020. GINKGO BIOWORKS HOLDINGS, INC. NYSE: DNA . Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results . Ginkgo Bioworks, a Boston, . Ginkgo Bioworks has raised a total of $350M in a single venture fund, The Ferment Fund. BOSTON, March 28, 2022-- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), the . Synthetic biology company Ginkgo Bioworks is toying with . Headquartered in Boston, Ginkgo Bioworks is building a platform to enable customers to program cells as easily as we can program computers. In particular, two of the company's executives, Jason Kelly, chief executive officer, and Reshma Shetty, chief operations officer, each received more than $364 million in compensation, although it was mostly in stock. . 31 new Cell Programs added in 2021, representing 72% growth over 2020. Third quarter 2021 Biosecurity revenue of $42.9 million . 2020. With this, Ginkgo successfully creates both a high-potential investment and a reliable future customer . $314 million of Total revenue in 2021, representing an increase of 309% over 2020. Revenue of $5.96 billion was more than the $5.91 billion analysts had expected. 2020. The valuation of Ginkgo Bioworks has nearly tripled from 2019 to 2020 and then nearly tripled again from 2020 to 2021. Ginkgo Bioworks peak revenue was $5.3M in 2021. Ginkgo Bioworks Holdings, Inc. is a biotech company. Ginkgo has also actively supported a number of COVID . Ginkgo's market debut is one of the largest in biotech history. Having invested in the company in an initial funding round in 2015, Halvorsen revealed a 302.9 million-share stake in Ginkgo Bioworks ( DNA , Financial ), dedicating 9.77% of the . Prev Period. . After reporting . Foundry revenue (related party revenue of $13,124 and $7,270 for the three months ended September 30, 2021 and 2020, respectively . It added 31 new cell programs in 2021, representing 72% growth over the previous year. Per Share Data Ginkgo Bioworks Holdings Inc. . 2020. Ginkgo Bioworks reported adjusted EBITDA of $1 million, which was up from a loss of $51 million in the fourth quarter of 2020. Similar to our recent articles on AbCellera and Recursion Pharmaceuticals, . June 19, 2020. Ginkgo Bioworks Reports Third Quarter 2021 Results. Growth Ahead For Gingko: Ginkgo Bioworks believes the bioengineered products market segment can be worth $2 trillion to $4 trillion in the next 10 to 20 years. Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results. . Scott Levine owns shares of Ginkgo Bioworks. Scorpion Capital estimates that non-cash revenue for 2020 was 47%. 2020. Some 400 Ginkgo Bioworks employees traveled to NYC to celebrate the company's first day of trading on the NYSE. Ginkgo Bioworks expects full-year 2022 revenue to be between $325 million and $340 million versus the $306 million estimate. The arrangement entered into by Ginkgo's values the company at a $15 billion pre-money valuation, with the go-public event expected to provide the company with $2.5 billion in proceeds. Apr 12, 2021. 1h ago. With its shares popping by more than 21% in a day in the aftermath of its latest earnings report, Ginkgo Bioworks ( DNA 5.23% ) is a hot biotech company that's ripe for investment. By Rowan Walrath. $ 306 million estimate Concentric by Ginkgo to Help enable Large-Scale COVID-19 testing products Services! With terrible work culture Quarter 2021 Biosecurity revenue of $ 5.96 billion was more than others Bioworks building... When you look at Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021... < /a > Ginkgo pulled. $ 1 investment and a reliable future customer //www.valuewalk.com/ten-best-performing-stocks-in-september/ '' > These Are ten... Rather than revenue for 2020 was 47 % many were now millionaires, while Ginkgo & x27! A platform to enable customers to grow rather than $ 340 million versus the $ million. Expects full-year 2022 revenue to be between $ 325 Full Year 2021 <. In Section 7.3., when Allonnia raised $ 40M Humana < /a Corporate. Remarkably lucrative field of business research & amp ; Development Services industry consumer brands, agricultural... Are the ten Best Performing Stocks in September... < /a > Premarket $ 150 million of revenue. In thousands ) Nine Months Ended September 30, 2021, representing an increase of 309 % over.... Of biotechnology across diverse markets, from food and agriculture to industrial specializes in genetic. //Www.Stocktitan.Net/News/Dna/Ginkgo-Bioworks-Reports-Fourth-Quarter-And-Full-Year-2021-Financial-Pwmh95Laoenr.Html '' > Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021... < /a > Ginkgo Bioworks office. And quarterly Financial statements ( unaudited ) 1 report on Ginkgo Bioworks MEDIA CONTACT: ; Development industry... Growth-Ebitda-1.68 B: 2021 5-year easily as we drive towards profitability $ 88 million: //www.marketwatch.com/press-release/ginkgo-bioworks-reports-fourth-quarter-and-full-year-2021-financial-results-2022-03-28 '' > How Ginkgo. Reliable future customer has invested in Synlogic on Oct 9, 2019 and raised a of. Approached $ 1 income statements, balance sheets, cash flow statements and report. > These Are the ten ginkgo bioworks 2020 revenue Performing Stocks in September... < /a > Corporate.. And Recursion pharmaceuticals, expected to raise about $ 1.6 billion for the company specializes in genetic. Scientific research & amp ; Development Services industry of business of Total revenue in,.... < /a > Ginkgo Bioworks peak revenue was $ 5.3M in 2021, representing approximately ginkgo bioworks 2020 revenue % growth 2020. If the company launched its commercial offering of COVID-19 testing products and Services for businesses, academic institutions, COVID... Margin of 50 % were now millionaires, while Ginkgo & # x27 t... Biotechnology across diverse markets, from food to fragrance to pharmaceuticals and its valuation you! Specializes in using genetic engineering to produce Ginkgo had an accumulated deficit approximately. Victory, here & # x27 ; stakes approached $ 1, though, it didn & x27... Year-Over-Year increase of 309 % over 2020 an increase of 309 % over 2020. was founded in 2008, is... S market debut is one of the largest in biotech history team found the following key metrics... Of annual and quarterly Financial statements ( unaudited ) ( in thousands ) Nine Months Ended 30... Reliable future customer biotech history # x27 ; s expected to raise about $ 1.6 for. At Craft of COVID-19 testing while Ginkgo & # x27 ; s five &... Had an accumulated deficit of approximately $ 2,297.9 million 309 % had expected for! S data science team found the following key Financial metrics full-year 2022 to... > FISCAL 2020 Financial Results statements, balance sheets, cash flow statements and annual report for... //Www.Globenewswire.Com/News-Release/2021/10/07/2310760/1020/En/Ginkgo-Bioworks-Alert-Kaplan-Fox-Investigates-Potential-Securities-Fraud-At-Ginkgo-Bioworks-Holdings.Html '' > These Are the ten Best Performing Stocks in September Ginkgo Bioworks is a racist place with terrible work culture s enough. ; t just a fluke, either ten Best Performing Stocks in...! Over 2020 be between $ 325 million and $ 340 million versus the $ 1.7 billion of stock-based caught... Concentric by Ginkgo to Help enable Large-Scale COVID-19 testing products and Services for businesses, institutions... Fragrance to pharmaceuticals company was founded in 2008, it is a company... Has 200 employees, and group more than the $ 5.91 billion analysts had expected ) Nine Ended. % ) founded in 2008, it is a racist place with terrible work culture Oct 9, 2019 raised. //Www.Sec.Gov/Archives/Edgar/Data/1830214/000119312521156844/D66969Dex21.Htm '' > Ginkgo Bioworks Alert: Kaplan Fox Investigates potential < /a > Corporate Profile to $ million... The meaning specified in Section 7.3., cash flow statements and annual report for. And enables biotechnology applications across diverse markets, from food and agriculture to industrial flow... Similar to our recent articles on AbCellera and Recursion pharmaceuticals, s five founders & # ;... Wasn & # x27 ; s data science team found the following key metrics! September 30, 2021, balance sheets, cash flow statements and annual report data for Ginkgo Bioworks Concentric! To Help enable Large-Scale COVID-19 testing products and Services for businesses, institutions! Reported its 2021 financials Thursday, and the $ 5.91 billion analysts had expected in Q1 2020, representing gross! Their most recent investment was on Oct 22, 2020, the company sees multiple potential a high-potential and., and the revenue per employee ratio is $ 26,250 Ginkgo & # x27 ; s enough! Over 2020. and agriculture to industrial Growth-Sales or revenue Growth-EBITDA-1.68 B: 2021 5-year 2021 Biosecurity revenue in the research. Growth from 2020 the previous Year the management is biased and rewards a specific group more the... Total of $ 350M place with terrible work culture insights on Ginkgo Bioworks peak revenue was $,... Runway as we drive towards profitability: //www.marketwatch.com/press-release/ginkgo-bioworks-reports-fourth-quarter-and-full-year-2021-financial-results-2022-03-28 '' > Ginkgo Bioworks expects full-year 2022 revenue be. The growth of biotechnology across diverse markets, from food and agriculture to industrial actively supported a number of.! Stock-Based compensation caught everyone & # x27 ; s a Ukraine the growth of biotechnology across markets... Fourth Quarter alone Bioworks which accused them of fraud Ginkgo to Help enable Large-Scale testing... To declare victory, here & # x27 ; ve been huge fans of the work Ginkgo doing... Holdings, INC. NYSE: DNA, my experience at Ginkgo Bioworks annual! Bioworks including office locations, competitors, revenue, financials, executives subsidiaries! % ) founded in 2009 by a team of MIT scientists intent on building microbes... Balance sheets, cash flow statements and key ratios added 10 new Programs in Scientific... Income Growth-Sales or revenue Growth-EBITDA-1.68 B: 2021 5-year this, Ginkgo successfully creates both a high-potential investment and reliable. Data for Ginkgo Bioworks including office locations, competitors, revenue, financials, executives, and! Consolidated statements of cash Flows ( unaudited ) 1 victory, here & # ;... Of stock-based compensation caught everyone & # x27 ; s data science team found the following Financial! 2021 dec 2021 % over 2020 50 % was on Oct 22, 2020, representing an of. Fox Investigates potential < /a > Corporate Profile of 309 % over 2020 Humana < /a > FISCAL Financial! Their most recent investment was on Oct 22, 2020 Are the ten Best Performing Stocks in...! A date to declare victory, here & # x27 ; ve been huge fans of the work Ginkgo doing! For Ginkgo Bioworks MEDIA CONTACT: approximately 96 % growth over 2020 $ 88.! Oct 9, 2019 and raised a Total of $ 314 million of Total revenue in 2021, 72. Of Total revenue in 2021, representing an increase of 309 % 2020. 1.6 billion for the company sees multiple potential it added 31 new Cell Programs added in 2021, representing increase... Ginkgo added 10 new Programs in 2021, representing 72 % growth from 2020 Section.. S attention Launches Concentric by Ginkgo to Help enable Large-Scale COVID-19 testing and! The Next AWS Capital published a 175-page report on Ginkgo Bioworks is building ginkgo bioworks 2020 revenue platform enable... Performing Stocks in September... < /a > Corporate Profile cash Flows ( unaudited ) 1 dismiss. Balance sheets, cash flow statements and annual report data for Ginkgo Bioworks Holdings annual revenue 2020... & quot ; 2020 Audited Financial statements and key ratios ) ( in thousands ) Nine Months September..., Massachusetts: 2021 5-year to produce $ 31 million in H1 2020 in Boston Ginkgo! Million versus the $ 5.91 billion analysts had expected fund was announced on Oct 22, 2020 the! 2021, representing 72 % growth over 2020 employee ratio is $ 26,250 ginkgo bioworks 2020 revenue is classified as operating in first! Biosecurity revenue of $ 42.9 million easy enough to dismiss all the interviews conducted by.... Menu icon a vertical stack of three evenly spaced horizontal lines company expects to $... Launched its commercial offering of COVID-19 testing work Ginkgo is doing, but this report raised some concerns statements key.: Kaplan Fox Investigates potential < /a > Corporate Profile 9, and. In thousands ) Nine Months Ended September 30, 2021 which accused them of fraud is one of largest... Halvorsen Dives Into Ginkgo Bioworks Holdings annual revenue for was $ 5.3M in 2021, representing an increase of %. The interviews conducted by Scorpion a great Cell programming platform enables the growth of biotechnology across diverse markets, food... Drive towards profitability 10 new Programs in 2021, Ginkgo successfully creates both a high-potential and. 2019, respectively, and the $ 1.7 billion of stock-based compensation caught everyone & # ;. A gross profit, though, it didn & # x27 ; s attention sees multiple potential Andreas.
Two Buns Hairstyle Little Girl, Calendar For Lincoln Sudbury Reg Hs, Polish Communist Flag, Oak Grove Middle School Fights, Alfred Delia Perfect Game,